Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Allergy

Sec. Skin Allergy

Case series: Combination of Dupilumab and Omalizumab as a way to reduce Dupilumab-associated adverse events in severe atopic dermatitis

Provisionally accepted
Daria S FominaDaria S Fomina1,2Olga A. MukhinaOlga A. Mukhina1,3*Elizaveta L. SedovaElizaveta L. Sedova1Marina S LebedkinaMarina S Lebedkina1Elena N. BobrikovaElena N. Bobrikova1Alexander V KaraulovAlexander V Karaulov4Mariana A. LysenkoMariana A. Lysenko1,5Harald RenzHarald Renz4,6
  • 1Moscow Clinical Research Center Hospital No. 52 of the Moscow City Health Department, Moscow, Russia
  • 2Pervyj Moskovskij gosudarstvennyj medicinskij universitet imeni I M Secenova Pediatriceskij fakul'tet, Moscow, Russia
  • 3Research Institute of Healthcare Organization and Medical Management of Moscow Department of Healthcare, Moscow, Russia
  • 4Pervyj Moskovskij gosudarstvennyj medicinskij universitet imeni I M Secenova, Moscow, Russia
  • 5Rossijskij nacional'nyj issledovatel'skij medicinskij universitet imeni N I Pirogova, Moscow, Russia
  • 6Philipps-Universitat Marburg, Marburg, Germany

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Dupilumab is a fully human monoclonal antibody directed against the interleukin-4 receptor subunit α (IL-4Rα), the common chain of IL-4 and IL-13 receptors. Dupilumab has been demonstrated to be highly effective in the treatment of severe atopic dermatitis, asthma, and chronic rhino sinusitis with nasal polypspolypous rhinosinusitis. Despite the favorable tolerability of Dupilumab, several publications and reviews have reported various adverse events, including conjunctivitis, keratitis, and face and neck treatment-resistant dermatitis, which reduce patients’ quality of life and may necessitate the cancellation of therapy. The current standard of care for severe chronic diseases involves a collaborative approach between the patient and their physician. The majority of patients who respond well to this type of systemic atopic dermatitis (AtD) therapy are reluctant toreluctant to interrupt Dupilumab treatment due to the previously mentioned adverse events. The combination of Dupilumab and anti-IgE therapy (Omalizumab) may be beneficial for individuals undergoing Dupilumab treatment for AtD and experiencing severe adverse events.

Keywords: Dupilumab, atopic dermatitis (AtD), Conjunctivitis, face and neck dermatitis, Dupilumab-associated adverse effects, Anti-IgE therapy, Omalizumab

Received: 01 Sep 2025; Accepted: 25 Nov 2025.

Copyright: © 2025 Fomina, Mukhina, Sedova, Lebedkina, Bobrikova, Karaulov, Lysenko and Renz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Olga A. Mukhina

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material